T2 Biosystems, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Craig R. Jalbert
- Full Time Employees
- 113
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 101 Hartwell Avenue Lexington MA United States of America 02421
- IPO Date
- Aug 7, 2014
- CIK
- 0001492674
- Website
- t2biosystems.com
- Similar Companies
- Business
- T2 Biosystems, Inc. (NASDAQ: TTOO) develops and commercializes innovative diagnostic products that detect pathogens directly from blood samples using magnetic resonance technology. The company's primary products include the T2Dx Instrument, a benchtop diagnostic platform; the T2Bacteria Panel, which identifies key sepsis-related pathogens such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecium, and Staphylococcus aureus; the T2Candida Panel for detecting Candida species including C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei; and the T2Resistance Panel, which screens for resistance genes associated with carbapenemase-producing organisms. T2 Biosystems also offers the T2Biothreat Panel for rapid detection of biothreat pathogens and related services including technical support, training, and reagent kits. Founded in 2006 and headquartered in Lexington, Massachusetts, the company operates primarily in the United States with distribution partnerships extending to Europe and the Middle East. In recent developments, T2 Biosystems entered a strategic distribution agreement with Salim Group in Indonesia in 2024 to expand access to its sepsis diagnostic panels in Southeast Asia; completed a public offering raising approximately $17.6 million in gross proceeds in early 2025 to support commercial growth and product development; and launched enhancements to its T2Dx platform software in late 2024 to improve workflow efficiency and data integration for hospital laboratories.
Financial Analysis: Biostage (OTCMKTS:BSTG) and T2 Biosystems (NASDAQ:TTOO)
Reviewing T2 Biosystems (NASDAQ:TTOO) & Acutus Medical (NASDAQ:AFIB)
T2 Biosystems (NASDAQ:TTOO) Shares Cross Below Two Hundred Day Moving Average – Should You Sell?
T2 Biosystems (NASDAQ:TTOO) versus Minerva Surgical (NASDAQ:UTRS) Head-To-Head Review
T2 Biosystems (NASDAQ:TTOO) Stock Price Passes Above 50 Day Moving Average – Here’s What Happened
T2 Biosystems (NASDAQ:TTOO) Shares Cross Above 50 Day Moving Average – What’s Next?
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens
T2 Biosystems, Inc. (TTOO) Q3 2024 Earnings Call Transcript
T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024
T2 Biosystems, Inc. (TTOO) Business Update Conference Call Transcript
T2 Biosystems to Host Business Update Call on October 10, 2024
T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
T2 Biosystems to Attend Upcoming Investor Conferences
T2 Biosystems, Inc. (TTOO) Q2 2024 Earnings Call Transcript
T2 Biosystems Announces Commercial Expansion Through Malaysia and Indonesia Distributor
T2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024
T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements